Drugs / 68Ga-NYM032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06389695 | Jun → Oct 2024 | prostate cancer | Norroy Bioscience Co., LTD | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07615101 | Jun 2026 → Jun 2027 expected | — | Norroy Bioscience Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NYM032 | “using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.” NCT07615101 ↗ |
| Known as | [68Ga]Ga-NYM032 | “The diagnostic efficacy of the PET tracer [68Ga]Ga-NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa...” PMID 39745526 ↗ Jan 2025 |
| Modality | Small molecule | “68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate cancer, which is needed for clinical trial to be conducted” NCT06389695 ↗ |
| Route | Intravenous | “the dose will be administered via an intravenous injection” NCT06389695 ↗ |